Erenumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and HAS (France), among others, recommended or restricted erenumab, while AOTMIT (Poland) did not recommend it.
Assessment has run over 6.1 years, from 27 Jun 2018 at AWMSG (Wales) to 2024 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2018, recommended by 2024, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 3 of 21 records date from 2023 or later.
4 distinct indication wordings are recorded for erenumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 21 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess erenumab, on 27 Jun 2018; PHARMAC (New Zealand) did not open a file until 22 Dec 2023 — a wide spread of 5.5 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 16 decisive outcomes narrowed erenumab to a subgroup rather than accepting or refusing it outright, at DMC (Denmark), NICE (England) and SMC (Scotland) among others.
6 of the 13 agencies here assessed erenumab more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
erenumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for erenumab reads 9 recommended, 4 restricted, 3 not recommended and 2 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Chronic migraine | Recommended | source |
| PHARMAC (New Zealand) | 22 Dec 2023 | Chronic migraine prevention | PTAC advice: High | source |
| HAS (France) | 30 Mar 2022 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| G-BA (Germany) | 21 Oct 2021 | Aimovig — benefit assessment §35a | added benefit: considerable (hint) | source |
| ZIN (Netherlands) | 27 Jun 2019 | Advies - niet vergoeden erenumab (Aimovig®) voor de behandeling van migraine | not reimbursed | source |
16 further decisions for erenumab, across 13 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- galcanezumab — same ATC class N02C — Analgesics
- fremanezumab — same ATC class N02C — Analgesics
- atogepant — same ATC class N02C — Analgesics
- rimegepant — same ATC class N02C — Analgesics
- eptinezumab — same ATC class N02C — Analgesics
- sumatriptan — same ATC class N02C — Analgesics
Coverage: 21 decisions for erenumab from 13 agencies, 2018 to 2024. Data to 7 Sep 2026. ATC class N02C — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.